Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case-control study.

Thiago Cerqueira-Silva Syed Ahmar Shah Chris Robertson Mauro Niskier Sanchez Vittal Srinivasa Katikireddi Vinicius de Araújo Oliveira Enny Santos da PaixãoIgor RudanJuracy Bertoldo JuniorGerson O PennaNeil PearceGuilherme Loureiro WerneckMauricio L BarretoViviane Sampaio BoaventuraAziz SheikhManoel Barral Netto

Published in: PLoS medicine (2023)

We observed that mRNA boosters after a primary vaccination course with either mRNA or viral-vector vaccines provided modest, short-lived protection against symptomatic infection with Omicron but substantial and more sustained protection against severe COVID-19 outcomes for at least 3 months.

Keyphrases

sars cov
coronavirus disease
binding protein
early onset
randomized controlled trial
respiratory syndrome coronavirus
systematic review
dna damage
dna repair
type diabetes
metabolic syndrome
weight loss